Picture Kentro Design Is Key to Your Success Berlin 650x100px
Document › Details

Abivax S.A.. (11/22/17). "Press Release: Abivax to Present at German Equity Forum 2017". Paris.

Region Region Frankfurt am Main
  Country Germany
Organisations Organisation Abivax S.A. (Euronext Paris: ABVX)
  Group Abivax (Group)
  Organisation 2 Deutsche Börse AG
  Today Deutsche Börse (Group)
  Group Deutsche Börse (Group)
Products Product Deutsches Eigenkapitalforum 2017 Frankfurt (German Equity Forum 2017)
  Product 2 obefazimod (ABX464)
Index term Index term Abivax–Deutsche Börse: investor conference, 201711 supply service Abivax presents at Deutsches Eigenkapitalforum 2017
Persons Person Ehrlich, Hartmut J. (Abivax 201410 CEO before Baxter BioScience 200712 VP Global RnD)
  Person 2 Carmagnol, Caroline (Alize RP 201107 CEO + Founder)

ABIVAX (Euronext Paris: FR0012333284 – ABVX), an innovative biotechnology company targeting the immune system to eliminate viral and inflammatory diseases, as well as cancer, today announces that the senior management of ABIVAX will present a corporate development overview at the upcoming German Equity Forum 2017 being held November 27-29, 2017 at the Sheraton Frankfurt Airport Hotel and Conference Center in Frankfurt am Main, Germany.

The presentation of Prof. Hartmut Ehrlich, M.D., CEO of ABIVAX is scheduled for Tuesday, November 28th, 11:30am CET in Room Oslo.

“ABIVAX is experiencing an exciting time as we have made excellent progress in the development of our product portfolio. Our lead candidate, ABX464, with the potential to induce a functional cure in HIV patients, showed early this year for the first time ever, that a therapeutic candidate could reduce HIV reservoirs in chronically infected patients – an effect which was confirmed with a second phase 2a study in September, said Prof. Hartmut Ehrlich, M.D., CEO of ABIVAX.

“In parallel, ABX464 showed also a promising anti-inflammatory effect in the intestine in a preclinical study, and, as a result, we have just started a clinical proof-of-concept study with this molecule in ulcerative colitis,” continued Prof Ehrlich.

“Furthermore, in October we presented the first preclinical proof-of-concept study showing that a second molecule, ABX196, an immune enhancer, significantly increases efficacy of anti-cancer drugs in preclinical models. These exciting data could truly change the company by opening the door to immune-oncology partnerships,” added Prof Ehrlich. Given all this, we strongly believe ABIVAX is passing through a transformative time and I am very much looking forward to discussing future developments and opportunities with investors and industry experts at this important event.”

The German Equity Forum hosted by German Stock Exchange “Deutsche Börse” is Europe's largest and most important capital market event for corporate finance. In addition, the organizers provide a central matchmaking platform for senior company representatives from various industries and the investment community. For more information about the event program, time frame and venue, please see the event website at

To schedule investor or media meetings with ABIVAX, please contact:

About ABIVAX (

ABIVAX is an innovative biotechnology company targeting the immune system to develop novel treatments for viral and inflammatory diseases as well as cancer. ABIVAX leverages three technology platforms for drug discovery: an antiviral, an immune enhancement, and a polyclonal antibody platform. ABX464, its most advanced compound, is currently in Phase 2 clinical trials for providing a sustained viral remission or functional cure for patients with HIV/AIDS. It is a first-in-class oral small antiviral molecule which blocks HIV replication through a unique mechanism of action and also has a strong anti-inflammatory effect, which is currently explored through a phase 2a proof-of-concept clinical trial in ulcerative colitis. In addition, ABIVAX is advancing a clinical stage immune enhancer for the treatment of cancer as well as multiple preclinical candidates against additional viral targets (e.g., Respiratory Syncytial Virus (RSV), Influenza and Dengue), and several of these compounds are planned to enter clinical development within the next 18 months. ABIVAX is listed on Euronext compartment B (ISIN: FR0012333284 – Mnémo: ABVX). More information on the company is available at

Follow us on Twitter @ABIVAX_


ABIVAX Finance
Didier Blondel
+33 1 53 83 08 41

Press Relations Europe
Caroline Carmagnol
+33 6 64 18 99 59

LifeSci Advisors
Chris Maggos
+41 79 367 6254

US Media
LifeSci Public Relations
Matt Middleman, M.D.
+1 646 627 8384

Press Relations and Investors Germany
MC Services AG
Anne Hennecke
+49 211 529 252 22

Record changed: 2023-06-05


Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Abivax (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner Top News Healthtech Company Mika 650x300px

» top